Abstract:Objectives and design:Developing an effective HIV-1 vaccine that elicits broadly neutralizing HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have revealed various strategies employed by the virus to escape host immune surveillance. Here, we investigated the human antibody gene repertoires of uninfected and HIV-1-infected individuals at genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput sequence analysis to determine the frequencies of putative germline antibody genes of known HIV-1 monoclonal bnAbs (bnmAbs).Methods:Combinatorial gDNA and cDNA antibody libraries were constructed using the gDNAs and mRNAs isolated from uninfected and HIV-1-infected human peripheral blood mononuclear cells (PBMCs). All libraries were deep sequenced and sequences analysed using IMGT/HighV-QUEST software (http://imgt.org/HighV-QUEST/index.action). The frequencies of putative germline antibodies of known bnmAbs in the gDNA and cDNA libraries were determined.Results and conclusion:The human gDNA antibody libraries were more diverse in heavy and light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely low in human antibody gene repertoires. However, we found relatively high frequencies of the heavy and kappa and lambda light chain variable regions that used the same V-genes and had the same CDR3 lengths as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such heavy and kappa and lambda light chain variable regions may be stimulated to induce HIV-1 bnAbs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

Identification and specificity of broadly neutralizing antibodies against HIV

Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Vaccination Induces Maturation of Diverse Unmutated VRC01-class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Development of Antibodies with Broad Neutralization Specificities Against HIV-1 after Long Term SHIV Infection in Macaques

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies